CTRI/2022/03/040898已完成3 期
Randomized, Multi-Centric, Comparative, Blinded, Parallel Group, Prospective Study, ToDetermine Clinical Efficacy And Safety Of Theruptor Surgical Wound Dressing of CareNow InComparison With Tegaderm of 3M and Plain Gauze dressing on Wound Healing In Patientsundergoing Abdominal and Joint surgeries.
CareNow Medical Pvt Ltd0 个研究点目标入组 210 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female of age 18 years or older.
- •2. Patient is willing to provide informed consent and is willing to participate
- •in all procedures and follow up evaluations necessary to complete the study.
- •3. Patients undergoing elective abdominal surgery/elective c-section
- •surgery/elective Joint surgery
排除标准
- •1. Patients with severe anemia - Hgb < 10 g/dL (males) or < 9 g/dL (females)
- •2. Patients with severe malnutrition (Albumin < 3.0 gm/dl; > 10% weight loss in preceding 4 weeks)
- •3. Patients with serum Creatinine more than 2 mg/dl
- •4. HbA1c more than 10% Patients with primary peritonitis and liver cirrhosis.
- •5.Patient who are taking medications that are considered immune system modulator.
- •6.Wounds in which incision edges are under high tension or not easily apposed (after deep layer suture).Wounds in which deep closure could not be achieved
- •7. Allergy to the test or comparator products employed in the study.
- •8. Wounds in which hemostasis is not able to be achieved, eg, drain is placed or Warfarin PT- INR level >2.5 prior to surgery
研究者
相似试验
尚未招募
2 期
To Determine Effectiveness ofTheruptor Sterile Barrier Wound Dressing In Chronic Infected woundsCTRI/2022/03/041044CareNow Medical Pvt Ltd
进行中（未招募）
1 期
Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon ß 1a) in Patients with Relapsing-Remitting Multiple SclerosisRelapsing-remitting Multiple SclerosisMedDRA version: 12.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2009-012500-11-FRBiogen Idec Ltd1,841
进行中（未招募）
不适用
Comparison of Daclizumab HYP and Avonex® in Multiple SclerosisRelapsing-remitting Multiple SclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-012500-11-DKBiogen Idec Ltd1,800
进行中（未招募）
不适用
Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon ß-1a) in Patients with Relapsing Remitting Multiple Sclerosis - NDRelapsing Remitting Multiple SclerosisMedDRA version: 12.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2009-012500-11-ITBIOGEN IDEC LTD1,500
进行中（未招募）
不适用
Comparison of Daclizumab HYP and Avonex® in Multiple SclerosisRelapsing-remitting Multiple SclerosisMedDRA version: 15.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-012500-11-SEBiogen Idec Ltd1,800